The Inside Scoop paBreast Cancer Treatment Costs muIndia - A Unofanira Kuverenga Zvakazarurwa!
Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading type of cancer. This serious disease must be treated at an early stage for the best outcomes. Our blog breaks down the breast cancer t..
Abemaciclib, aromatase inhibitor, Eli Lilly uye Kambani, endocrine kurapwa, Tamoxifen, Verzenio
Abemaciclib ine endocrine therapy inotenderwa neFDA muHER 2 yakanaka kenza yemazamu
Kurume 2023: Abemaciclib (Verzenio, Eli Lilly uye Kambani) uye endocrine therapy (tamoxifen kana aromatase inhibitor) zvakabvumidzwa neFood and Drug Administration (FDA) yekurapa adjuvant yevarwere vakuru vane ..
China, Enhertu, HER 2 positive
Enhertu yakatenderwa kuChina kune varwere vane HER2-positive metastatic cancer yemazamu
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..
Hamsa, Hamsa Nandini, Mirchi, Mirchi movie
Mutambi Hamsa Nandini Anopa Ruzivo Rwegore Rimwe Mushure meKurapwa Gomarara Repazamu
Kukadzi 2023: Hamsa Nandini, akabatwa Grade III Invasive Carcinoma (Breast Cancer) muna 2021, akavandudza vateveri vake ve Instagram nezvehutano hwake. Mutambi, akaonekwa mumafirimu eTelugu akadai saMirchi naLege.
Girasi Sciences, sacituzumab govitecan-hziy, Trodelvy, TROPiCS-02
Sacituzumab govitecan-hziy inotenderwa neFDA yeHR-positive cancer cancer
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
elacestrant, Orserdu, Stemline Therapeutics
Elacestrant inotenderwa neFDA yeER-positive, HER2-negative, ESR1-yakashandurwa yepamusoro kana metastatic cancer yemazamu.
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..
Daiichi Sankyo, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki inotenderwa neFDA yegomarara rezamu
Kubvumbi 2022: Varwere vakuru vane isingarambike kana metastatic HER2-yakanaka kenza yemazamu avo vakagamuchira yekutanga anti-HER2-yakavakirwa regimen kungave mune metastatic kurongedza, kana mune neoadjuvant kana adjuvant kuseta uye vakakura.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
Olaparib inotenderwa kurapa adjuvant yegomarara rekutanga rezamu
Kurume 2022: Iyo Chikafu neDrug Administration yakabvumidza olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) yekurapa adjuvant yevarwere vakuru vane inobvisa kana fungidziro yekubvisa germline BRCA-mutated (gBRCAm) h.
Abemaciclib, Agilent, Dako Omnis, Eli Lilly uye Kambani, endocrine kurapwa, Tamoxifen, Verzenio
Abemaciclib inotenderwa neFDA ine endocrine kurapwa kwekutanga kenza yemazamu
Gumiguru 2021: Chikafu neDrug Administration yakabvumidza abemaciclib (Verzenio, Eli Lilly neKambani) pamwe chete ne endocrine therapy (tamoxifen kana aromatase inhibitor) yekurapa adjuvant yevarwere vakuru vane chirwere ichi.
KEYTRUDA, Merck, Pembrolizumab, TNBC kuwedzera
Pembrolizumab yakagamuchirwa neDFA kune yakanyanya njodzi njodzi-yekutanga katatu-isina kenza yemazamu
Nyamavhuvhu 2021: Pembrolizumab (Keytruda, Merck) yakagamuchirwa neDFA kune yakanyanya njodzi, yekutanga-nhanho katatu-isina kenza yemazamu (TNBC) senge neoadjuvant kurapwa mukubatana nekemotherapy, uye gare gare seimwe chete mumiriri seadjuv ..